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Abstract:
Introduction: The United States has been battling an opioid epidemic for decades. As substance
use disorders have grown, so too has investigation into treatment options, including integrative
medicine approaches, for managing opioid withdrawal symptoms (OWS).

Objectives: This systematic review sought to assess the use of integrative medicine approaches
for the alleviation of OWS in patients dependent on opioids and to summarize the available data.

Methods: The authors searched using synonyms for opioids, substance use disorder, and
integrative medicine and standardized searches in Embase, PubMed, and Cochrane Library. We
also hand searched references for systematic reviews. This review did not include articles that
could not be obtained as full-text publications via interlibrary loan. The review also excluded
studies with interventions involving acupuncture because multiple systematic reviews on this
approach already exist. In addition, we also excluded studies of therapy for opioid maintenance.
We evaluated studies for inclusion based on the Jadad criteria. We compared opioid withdrawal
outcomes of the studies to determine the efficacy of integrative medicine approaches.

Results: The authors identified a total of 382 unique publications initially for possible inclusion
through systematic searches. After applying inclusion and exclusion criteria, five studies met
Jadad criteria. The authors identified an additional two studies for inclusion via hand searching.
A total of seven studies included interventions consisting of passionflower, weinicom, fu-yuan
pellet, jinniu capsules, tai-kang-ning, dynorphin, and l-tetrahydropalmatine. Analyzing the
articles was difficult given the varied scoring methods they used to quantify opioid withdrawal

symptoms and the small sample sizes in the trials. Most showed evidence that supported
integrative medicine approaches for OWS, although the strength of evidence was limited because
of sample sizes.

Conclusions: This review found evidence of multiple integrative medicine approaches for opioid
withdrawal symptoms. Well-designed randomized controlled trials should assess the efficacy of
integrative medicine for improvement in OWS.

1.0 Introduction:
In 2017, 191 million opioid prescriptions were written in the United States, the first time
in ten years that the number of prescriptions written for opioids has been below 200 million per
year.1 Although progress is being made toward reducing the number of opioids prescribed in the
United States in light of the opioid epidemic, the opioid prescribing rate remains high at 58.7
prescriptions per 100 persons.1 As patients and prescribers become increasingly aware of opioid
use disorder, the identification of effective withdrawal treatments is vital to patient safety and
comfort.
Opioid withdrawal symptoms (OWS), including agitation, insomnia, diaphoresis,
tachycardia, and many others, can be debilitating for many patients.2,3 Symptoms can start as
early as six hours after the last dose of an opioid and peak around 72 hours after last use.2
Although OWS may not be life-threatening, unassisted withdrawal can increase the risk of
relapse.2
Fear of opioid withdrawal syndrome is a contributing factor to the cycle of abuse in
individuals who misuse opioids.4 In current practice, opioid withdrawal is managed either
through the gradual taper of opioid agonists, such as methadone or buprenorphine, or through the
use of nonopioids, such as clonidine for symptoms.3 Alpha-2 agonists, such as lofexidine, FDA
approved for OWS, and clonidine, used off label, are sometimes combined with other
prescription medications to combat specific withdrawal symptoms. For example,
benzodiazepines are sometimes used for anxiety during withdrawal, although they should be
used with caution due to known risk of dependence .3
Although buprenorphine and clonidine are useful in diminishing symptoms, some
individuals may be interested in integrative medicine approaches for OWS. However, despite

increased interest in integrative medicine for OWS, clear guidance and evidence is lacking. The
purpose of this systematic review is to identify and evaluate available evidence regarding
integrative medicine for opioid withdrawal symptoms.

1.1 Methods:
1.1.1 Protocol and Registration: The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses statement was used to conduct this systematic review.
1.1.2 Literature Search: Three databases, Pubmed, Embase, and Cochrane Library, were
searched for studies investigating the efficacy of integrative medicine on symptoms of opioid
withdrawal. The search strategy consisted of using a combination of synonyms from three baseterm categories, including “opioids”, “substance use disorder”, and “integrative medicine”.
Thirty combinations were searched systematically in each database and included one term from
the integrative medicine category, one term from the substance-use-disorder category, and the
standard opioid term sequence. All three categories were connected using the Boolean term
“AND”. Medical Subject Headings terms were used for Pubmed and Cochrane Library, while
Emtree terms were used for Embase. Specific terms were determined via the database’s preferred
terminology. For the integrative-medicine-terms category, the terms “Integrative Medicine”,
“Complementary Therapies” (Emtree preferred term: “Alternative Medicine”), “Medicine,
Chinese” (Emtree preferred term: “Chinese Medicine”), “Biological Products” (Emtree preferred
term: “Natural Products”), and “Herbal Medicine” were searched systematically. For the
substance-use-disorder category, the terms “Substance Withdrawal Syndrome” (Emtree preferred
term: “Withdrawal Syndrome”), “Opioid-Related Disorders” (Emtree preferred term: Opioid Use
Disorder”), and “Substance-Related Disorders” (Emtree preferred term: “Drug Dependence”)

were used. Additionally, “Opioid Withdrawal” and “Detoxification AND Opiate” were used in
Emtree, but no corresponding term was found in the Medical Subject Headings terms database.
For the opioid category, “Heroin”, “Morphine”, “Analgesics, Opioid” (Emtree preferred term:
“Opiate”), “Codeine”, and “Narcotics” (Emtree preferred term: “Narcotic Agent”) were utilized
for each search as a sequence connected by the Boolean term “OR”. The studies were filtered for
human subjects, the English language, and the dates January 1, 1968 - January 1, 2019. Articles
that evaluated the use of acupuncture for opioid withdrawal were excluded from this systematic
review because of the comprehensive body of data available when compared to the results of
other, lesser-known integrative medicine approaches. After the initial search outlined above was
completed, a hand search of the references was conducted to gather any additional potential
pertinent articles.
1.1.3 Eligibility: Two authors (CC and CK) used titles and abstracts to screen articles’
findings from the three databases. Only randomized controlled trials, case-control studies, or
cohort studies that evaluated the efficacy of integrative medicine approaches on symptoms of
opioid withdrawal in adults were included for analysis. Studies that focused on prescription
medication as the test intervention or focused on symptoms during the maintenance phase of
treatment were ineligible. Additionally, abstracts or citations were not considered for analysis if
full-text English versions could not be obtained via interlibrary loan.

Unique articles from initial
database search
(n=392)
Handsearching of articles
completed and exclusion
criteria applied
Articles identified for inclusion
(n=47)
Studies excluded for not
meeting a Jadad > 3
Full-text articles included with
a Jadad > 3
(n=7)
Fig. 1: Flow diagram of the systematic review process employed in this review.

1.1.4 Study Selection, Data Extraction, and Analysis: Upon completion of initial
eligibility screening, two authors (CC and CK) independently scored full-text articles using a
Jadad scale to assess the quality of the studies. The Jadad scale was chosen because it aims to
reduce bias in studies by assessing elements of randomization, blinding, and participant
accountability.5 Studies needed to meet a Jadad score of three or higher to be included.
Conflicts of any Jadad scores were resolved through independent scoring by two
additional authors (KW and AH). Once article selection was finalized, two authors (CC and CK)
each independently extracted data to be subsequently verified by the remaining three authors.
Researchers assessed study design, the specific integrative medicine approach, comparator
group(s), participant population, assessment tools used in the trial, outcomes, and results.
Three hundred and ninety-two unique articles were found during the initial database
search. After a hand-search for additional articles was completed and exclusion criteria were
applied to all potential articles, 47 articles were considered for inclusion, but only seven met the
Jadad criteria and were included in the review.
Table 1
Summary of Articles Included in Systematic Review

Study
Information

Patient
Population

Care
setting,
Duration

Intervention

Yang Z, et al. ●
Acta Pharmacol
Sin. 2008;29: ●
781–8.

27.57+5.76
years old
Heroin
dependence
by DSM-IV

Inpatient,
5 months

l-THP 60 mg
twice daily
(n=59)

Placebo twice
daily (n=44)

・ Urine sample
・ Heroin
Withdrawal Scale
(PAWS, scale
range: 0-120)

・ After two weeks, survival probability of retention for placebo
was 100% (95% CI: 100%) and 72% (95% CI: 60-83%) for lTHP
○ The dropout rate in the l-THP group was significantly higher
than placebo (P<0.0001) [l-THP group went from 61→ 44
subjects, placebo group remained at 59 subjects]
・ l-THP group had a higher abstinence rate at 3 month follow-up:
47.7% (95% CI: 33-67%) vs 15.2% (95% CI: 7-25%);
P=0.0005
・ One month of l-THP significantly reduced overall PAWS
severity; p<0.0001
○ Mean craving scores at the start of treatment were 41.61 +/2.79 (l-THP versus 41.72 +/- 2.27 (placebo)
○ Mean craving scores one month after treatment began were
23.00 +/- 1.91 (l-THP) versus 25.26 +/-1.47 (placebo)
○ Mean craving scores one month after cessation of treatment
were 3.5+2.6 (l-THP) versus 7.0+3.5 (placebo); P<0.01
○ A subanalysis of somatic syndrome, insomnia, and craving
met statistical significance

Akhondzadeh ・ Men only
S, et al. J Clin ・ DSM-IV
Pharm Ther.
criteria for
2001; 26: 369opioid
73.
dependence

Outpatient,
14 days

Clonidine,
0.3mg
increased to
0.8mg by day
4, plus
Passiflora
extract, 60
drops per day
(n=15)

Clonidine,
0.3mg
increased to
0.8mg by day
4, plus
Placebo, 60
drops/day
(n=15)

・ SOWS (scale
range: 0-30)
・ Expanded SOWS
to include mental
symptoms and
diarrhea (scale
range: 0-48)

・ Physical symptoms: both groups experienced a decrease in
scores, however differences between the groups were nonsignificant
・ Mental symptoms: both groups saw improvements in scores
over time. Statistically significant differences in scores favoring
passiflora extract were found beginning on the second day and
continuing to the end of 14 days, though no p value was
reported
○ Clonidine group had significantly increased scores compared
to passiflora extract on days 2, 3, 4, 7, 14
・ Total scores: significantly decreased by both treatments, but the
total score by day 14 in the clonidine group was significantly
higher than the passiflora group (p=0.011)

Wen HL, et al. ・ 30-38 years
Eur J
・ Men with
Pharmacol
chronic
1982;82:183-6.
heroin
abuse
・ Relapse
history

Inpatient,
2 hours

Shi J, et al. Am ・ 18-50 years
J Drug
・ Opiate
Alcohol Abuse.
dependence
2008; 34:792by DSM-IV
800.

ATC, 10
days

・ Dynorphin IV,
60 mcg/kg,
then saline IV
one hour later
(n=6)
OR
・ Saline IV then
dynorphin IV,
60 mcg/kg, one
hour later (n=6)
Tapered
Jinniu:
Day 1-3: 2.5g
three times
daily
Day 4-5: 2.0g
three times
daily
Day 6-7: 1.5g
three times
daily
Day 8-9: 1.5g
twice daily
Day 10: 1.5g
once (n=99)

Comparator

Analysis Test

Outcomes and Results

2 injections of ・ MKHP (scale
IV saline given
range: no upper
1 hour apart
limit
(n=6)

・ Decreased withdrawal scores after dynorphin given as the first
injection (0.01 < P < 0.05)
○ A sustained decrease during the 1-hr period after saline
injection [P<0.05 (nurse assessment), P<0.02 (patient
assessment)]
・ Decreased score after dynorphin given as the second injection
whether compared to baseline or to the scores after saline given
as the first injection

Tapered
・ Opioid
lofexidine:
Withdrawal Scale
Day 1: 0.4mg
(scale range:
three times
unknown)
daily
・ HAMA (scale
Day 2-5:
range: 0-56)
0.6mg three
times daily
Day 6-7:
0.4mg three
times daily
Day 8-9: 0.2 or
0.4mg once
daily
Day 10: 0.2mg
(n=104)

・ Total opioid withdrawal scale scores decreased for both groups,
but no significant difference between groups over the ten-day
course
・ Main opioid symptom score reduction: no significant
differences between groups
・ HAMA: no significant differences in anxiety reductions
between groups
○ Day 0: 28.13 +/- 5.42 (Jinniu) versus 27.63 +/- 4.84
(lofexidine)
○ Day 5: 9.45 +/- 5.93 (Jinniu) versus 8.96 +/- 5.38
(lofexidine)
○ Day 10: 2.58 +/- 2.35 (Jinniu) versus 2.65 +/- 2.39
(lofexidine)

Wang, X, et al.
Am J Drug
Alcohol Abuse
2009; 35: 40811.

・

18-55 years
Heroin
dependence
by DSM-IV

ATC, 10
days

Tapered FYP:
Day 1-3: 6.0g
three times
daily
Day 4-6: 8.0g
three times
daily
Day 7-10: 8.0g
twice daily
plus matching
placebo
(n=104)

Tapered
lofexidine:
Day 1: 0.4mg
twice daily
Day 2-4:
0.6mg three
times daily
Day 5-6:
0.4mg three
times daily
Day 7-8:
0.4mg twice
daily
Day 9-10:
0.2mg twice
daily plus
matching
placebo
(n=103)

・ Withdrawal
syndrome rating
scale (scale range:
unknown)9
・ HAMA (scale
range: 0-56)

・ Daily total withdrawal syndrome rating scale scores: both
groups had day by day significant decrease ( P =0 .0001)
○ Both groups met the effective threshold of >50% reduction
rate on day 3 (FYP: 58.93%, lofexidine: 60.01%)
○ No significant difference between groups for daily total
scores or daily reduction rate
・ Daily total HAMA score: no significant difference between
groups
・ Adverse effects: lofexidine group (42.34%) vs FYP group
(14.29%)*; P<0.001

Kang L, et al.
Am J Drug
Alcohol Abuse
2008;34: 26976.

・ 18-65 years
・ Heroin
dependence
by DSM-IV

ATC, 10
days

Tapered TKN:
Day 1-5: 2.0g
three times daily
Day 6-7: 1.5g
three times daily
Day 8-9: 1.5g
twice daily
Day 10: 1.5g
once plus
placebo
lofexidine
(n=28)

Tapered
・ Withdrawal
lofexidine:
syndrome rating
Day 1: 0.4mg
scale (scale range:
twice daily
unknown)18
Day 2-5: 0.6mg
three times daily
Day 6-7: 0.4mg
three times daily
Day 8-9: 0.2mg
or 0.4mg once
Day 10: 0.2mg
plus placebo
(n=31)

・ Daily total withdrawal syndrome rating scale scores: both
groups had day by day significant decrease (P = 0.0001)
○ Both groups met the effective threshold of >50% reduction
rate on day 3 (TKN: 55.94%+16.24%) vs lofexidine:
64.48+15.06%)
○ No significant difference between groups for daily total
scores
・ Adverse effects: TKN: 62.5% vs. lofexidine: 65.6%

Inpatient,
14 days

WeiniCom, 810 capsules
four to six
times daily,
gradually
tapered to zero
by day 9-10,
and matching
placebo (n=21)

BUP 0.9・ Withdrawal
1.2mg
Symptom Rating
intramuscularl
Scale (0-57)
y twice daily, ・ Craving Rating
tapered by
Scale (0-504)
0.3gm every
・ Side Effects
other day, and
Rating Scale (0matching
57)
placebo (n=21)

・ All patients retained for 14 days
・ Withdrawal symptom scores decreased over time:
○ Day 5, mean scores: 19.4 for BUP vs. 12.6 for WeiniCom;
P<0.05
○ Day 6, mean scores: 16.7 for BUP vs. 9.6 for WeiniCom;
P<0.05
○ Day 9, mean scores:15.2 for BUP vs. 5.2 for WeiniCom;
P<0.05
・ The decline in psychological craving was greater for
WeiniCom:
○ Day 3: buprenorphine psychological rating score was 100.0
versus 43.3 for WeiniCom; P<0.05
・ Adverse effects were similar between groups
・ No significant differences in blood, urine, liver, and kidney
function tests or electrocardiograms between groups

・

Hao W, et al.
・ Heroin
J Psychoactive
dependence
Drugs. 2000;
by DSM-IV
32:277-84.

ATC = addiction treatment center, BUP= Buprenorphine, DSM= Diagnostic and Statistical Manual of Mental Disorders, FYP=Fu-Yuan Pellet HAMA=
Hamilton Anxiety Scale19, MKHP=Modified Kolb and Himmelsbach procedure, SOWS= short opioid withdrawal scale, TKN= Tai-Kang-Ning
*All adverse effects in the study resolved without treatment

1.2 Results:
Table 1 summarizes findings from the seven trials of integrative medicine identified for
inclusion. Studies evaluated the use of integrative medicine approaches on multiple aspects of
opioid withdrawal syndrome, including drug cravings, drug abstinence, and physical symptoms.
Trials were conducted primarily in an inpatient care setting and used different assessment scales,

although all scales were focused on common OWS. All trials were randomized and six were
double-blind while one trial employed a single-blind procedure. More than half of the trials used
a standard of therapy for OWS as a comparator group or at baseline. Of note, an understanding
of the natural course of opioid withdrawal, including that symptoms generally begin to decline
after 3-5 days, is important to consider in evaluating the literature.
1.2.1 Studies with a placebo comparator arm
Levo-tetrahydropalmatine (l-THP)
Levo-tetrahydropalmatine (l-THP) is a traditional Chinese herb believed useful for drug
craving and relapse with no abuse potential.7 One study evaluated the use of l-THP for protracted
opioid withdrawal syndrome (PAWS) after seven to ten days of detoxification among heroin
users. Notably, participants were abstinent from opioids for at least seven days before beginning
the trial. Subjects were randomized to receive 60 mg of l-THP or matching placebo twice daily
for one month. Participants were evaluated for abstinence weekly through urine samples and for
opioid withdrawal symptoms via the Heroin Withdrawal Scale during the active medication
period and every two weeks thereafter for four months. The protracted abstinence withdrawal
symptoms scale scored patients on symptoms in four categories: somatic, mood, insomnia, and
heroin craving. The l-THP group had a lower retention rate at the two-week treatment mark
compared to placebo. The participants who persisted in the trial were more likely to be abstinent
after three months when compared to the placebo group, suggesting the first two weeks of
therapy pose the greatest risk of relapse. Additionally, treatment with l-THP for one month was
associated with a significant reduction in PAWS severity by the conclusion of the trial,
specifically in regard to somatic syndrome, insomnia, and cravings. Study results indicated the

importance of treatment past the typical one to two week window in which most patients
experience withdrawal symptoms.
Passionflower drops
Passionflower (Passiflora incarnata) vine is known for its anxiolytic and sedative effects,
recognized by the Commission E in 1995 and the British Herbal Compendium in 1996.10 One
trial investigated the use of passiflora extract as an adjunct to clonidine for outpatient
detoxification.10 Thirty medically healthy men with opioid dependence as defined by DSM-IV
were given 0.8 mg/day of clonidine divided into three daily doses and randomized to receive
either 60 drops of passiflora extract or placebo three times daily for 14 days. The clonidine dose
was tapered up from 0.3 mg/day to 0.8 mg/day in the first four days of the start of the trial.
Further details of dosing were not provided by the study. Participants were assessed using the
Short Opioid Withdrawal Scale (SOWS) expanded to include questions about mental symptoms
and diarrhea. By day 14, both groups demonstrated a significant decrease in withdrawal
symptoms based on the SOWS, but no significant difference was found between groups.
However, a statistically significant difference was found between the two groups in regard to
mental symptom scores, favoring the use of passiflora for mental symptoms, such as dysphoria,
agitation, anxiety, and irritability. When taking into account SOWS scores, mental symptom
scores, and diarrhea symptom scores, the placebo group had significantly increased mean total
scores on day 14 than the passiflora group favoring the use of passiflora. Both the passiflora and
placebo groups had large numbers of unexplained dropouts during the study, 15 and 20
participants, respectively. This trial may be too small and inadequately powered to adequately
demonstrate efficacy for the addition of passionflower drops to clonidine for OWS.
Dynorphin

Dynorphin-(1-13) is a synthetic opioid agonist that has preliminary data on attenuating heroin
withdrawal symptoms.11 In one trial, 18 men with longstanding heroin use were admitted to an
inpatient care facility and randomized to one of three treatment groups upon demonstration of
OWS.11 Two consecutive injections were given to patients one hour apart, either saline/saline,
dynorphin/saline, or saline/dynorphin. The opioid withdrawal symptoms were scored using the
Modified Kold and Himmelsbach procedure. Patients were scored for symptoms of opioid
withdrawal every 15 minutes for one hour after each of the two injections. In both groups which
received one 60 μg/kg injection of intravenous (IV) dynorphin, withdrawal scores were
significantly decreased after injection. In the group that received a dynorphin injection first,
saline did not result in any further lowering of opioid withdrawal score, however, scores
remained low, suggesting a prolonged effect of dynorphin. In the group receiving the dynorphin
injection second, withdrawal scores also decreased during the observation period. In regard to
safety, three of the twelve patients displayed minor precordial formication, one reported feeling
warm, and another dizzy.

1.2.2 Studies with an active comparator arm:
Jinniu capsules
One trial investigated the safety and efficacy of Jinniu capsules, a traditional Chinese
medicine product containing a blend of eight herbs, compared to lofexidine, an alpha-2
adrenergic agonist, for OWS.6 Two hundred and twelve patients were randomized to a ten-day
tapered regimen of Jinniu or lofexidine with tapering doses ranging from 7.5 g to 1.5 g/day and
1.8 mg to 0.2 mg/day, respectively. Supplemental medications were allowed, including the use
of estazolam and clonazepam. Patients were assessed via an Opiate Withdrawal Scale, with an

emphasis on drug craving, lacrimation, anxiety, diarrhea, abdominal pain, bone and muscle ache,
and insomnia as well as the Hamilton Anxiety Scale. Overall, opioid withdrawal symptoms and
anxiety scale scores declined in the study and were similar between the groups. In terms of
adverse events, Jinniu capsules were associated with blurred vision, dizziness, and dry mouth,
while lofexidine was associated with dizziness, postural hypotension, and dry mouth.
Fu-yuan pellet
Fu-Yuan Pellet (FYP) is a ten herb traditional Chinese medicine product containing Largehead
Atractylodes Rhizome, Hawthorn Fruit, Glabrous Greenbrier Rhizome, Tangshen, Prepared
Dried Ginger, Eucommia Bark, Divaricate Saposhnikovia Root, Excrementum Pteropi,
Desertliving Cistanche, and Dried Tangerine peel believed to be beneficial for OWS.8 One study
compared the safety and efficacy of FYP versus lofexidine for symptoms of opioid withdrawal.8
Two hundred and twenty-five participants were randomized to receive a ten-day taper of FYP
with doses ranging from 24 g/day to 16 g/day or lofexidine 1.8 mg/day to 0.4 mg/day. The 23item withdrawal syndrome rating scale in the Principle of Clinical Trial
of Anti-Opiate Withdrawal Drug was used to evaluate efficacy.9 Both treatments were
considered effective as a score reduction of at least 50% was observed by the third day of
treatment in both groups. Daily total scores, daily reduction rates, and total anxiety scale scores
were similar between the two groups. Dry mouth was the most commonly reported adverse
effect in both groups. Although lofexidine and FYP demonstrated similar efficacy, FYP was
associated with significantly fewer adverse effects than lofexidine.
Tai-Kang-Ning capsules
Another study evaluated Tai-Kang-Ning (TKN) capsules, a blend of eight herbs
hypothesized to aid opioid addiction recovery, against lofexidine for symptoms of opioid

withdrawal.12 Sixty-four patients with acute heroin withdrawal were randomized to receive either
TKN in a regimen tapering the dosage from 6 g/day to 1.5 g/day or lofexidine tapered from 1.8
mg/day to 0.2 mg/day. Patients were evaluated using a withdrawal syndrome rating scale. Both
treatments were considered effective because a withdrawal symptom score reduction rate of over
50% was observed by the third day of treatment in both groups. Furthermore, total scores for
withdrawal syndrome decreased over the ten-day treatment course. Significant differences were
not found between groups in either the daily total scores or the daily reduction rate.
WeiniCom capsules
WeiniCom, also known as Xuan Xia Qudu Jiaonang, is a blend of Chinese herbs
including extracts of Glycyrrhiza glabra, Zingiber officinalis, Nauclea Spp, and Epimedium
grandifora, among others. The product is believed to alleviate symptoms of opioid withdrawal in
traditional Chinese and Ayurvedic medicine.13 One study evaluated the use of WeiniCom
capsules compared to buprenorphine for the reduction in OWS and for adverse effects.14 Fortytwo subjects were randomized to treatment with either 8-10 capsules of WeiniCom four to six
times daily, tapered to a dose of zero on treatment days nine and ten or buprenorphine 0.9-1.2 mg
intramuscularly twice daily in tailored doses, tapered by 0.3 mg every other day until a dose of
zero. In both arms, benzodiazepines (triazolam 0.75-2.5mg/day) were prescribed for patients
with sleep problems or anxiety, the study reports that the use of benzodiazepines between groups
was similar. Subjects were treated for 14 days. Both treatment and control groups experienced a
decrease in Withdrawal Symptom Rating Scale scores and Craving Rating Scale scores over
time. Significant differences between groups in regard to withdrawal symptoms were seen on
days five, six, and nine of treatment in favor of WeiniCom. However, the assessments used were
not validated at the time of the study. Furthermore, the trial failed to show significant findings

consistently, rather, some treatment days were considered significant over others. These daily
variances in significant findings have limited clinical applicability.

1.3 Discussion:
This systematic review was conducted to evaluate available evidence for the use of
integrative medicine for the symptoms of opioid withdrawal. The integrative medicine
approaches demonstrate potential benefits on selected symptoms of opioid withdrawal and in
some studies, subsequent abstinence from opioid use, either as monotherapy or as an adjunct to
clonidine, lofexidine, or buprenorphine. Passiflora and Tai-Kang-Ni were evaluated as
adjunctive medications while Jinniu capsules, Fu-Yuan pellets, and WeiniCom were compared to
prescription medications as monotherapy. Levo-tetrahydropalmatine and dynorphin were
compared as monotherapy to placebo arms.
Both the intervention and comparator arms in each active-comparator trial included in
this review demonstrated efficacy for opioid withdrawal symptoms, however the efficacy was
often non-significant between study arms. Weinicom demonstrated significantly lower symptom
scores than the comparator arm on multiple days, but the variances in statistical significance in
day-to-day scores have limited clinical applicability. Similar safety profiles were seen for the
integrative medicine approaches overall, except for Fu-Yuan pellets which had fewer adverse
effects than the lofexidine comparator arm. A notable limitation of the active-comparator studies
is the inadequate dosing of the comparator arms. For example, the lofexidine groups in the FYP,
TKN, and Jinniu capsule trials may be considered underdosed. Current recommendations for the
use of lofexidine in opioid withdrawal are 0.54 mg four times daily for five to seven days.16 The
studies utilized lofexidine 0.6 mg three times daily as the maximum dose and this underdosing

could contribute to a lack of significant findings. Additionally, the use of buprenorphine given as
an intramuscular injection for OWS, as in the WeiniCom trial, is not indicated, thereby
decreasing the trial’s potential applicability. Furthermore, a number of trials allowed adjuvant
medications such as benzodiazepines for patients having insomnia or agitation. The addition of
adjuncts on outcomes was not expressly evaluated and should be considered as a potential
confounder to the use of integrative medicines.
All of the placebo-comparator studies saw significant reductions in withdrawal symptoms
of active treatment compared to placebo. The passionflower study suggested that passiflora may
have favorable effects in regard to mental symptoms of opioid withdrawal specifically but
concerns over the extensive number of unexplained dropouts may limit the applicability of the
findings. The l-THP study found improvements in overall PAWS and abstinence rates at the end
of the three month trial for those who continued after the first two weeks of treatment. In the
dynorphin study, participants demonstrated significantly decreased withdrawal scores after
dynorphin administration, however the small study population may hinder the reliability of these
findings and the participants were following for no longer than two hours, the shortest followup
of all the trials. In the passiflora and l-THP studies, data and discussion of adverse effects were
lacking. The passiflora trial used clonidine in an appropriate dose, given current practice
recommendations suggesting the use of clonidine in doses of 0.1 mg-0.2 mg two to four times
daily.17
Overall, multiple assessment scales with varied follow-up periods were used to determine
effectiveness for physical and/or mental symptoms of withdrawal. A comparison between
treatments is difficult given the differences in the assessment. For example, the OWS and Kolb
& Himmelsbach procedures assess symptoms over a 24-hour period while the SOWS evaluates

immediate responses.15 Thus, the definition of adequate follow-up for integrative medicine
approaches remains uncertain.
The participants in the trials varied in their duration of opioid use disorder, additional
substance misuse, and time since last use. In general, trials had a small patient population
composed primarily of men. Both the passionflower and dynorphin studies only used male
participants, while the WeiniCom, l-THP, TKN, and Jinniu studies had 88%, 75%, 83%, and
86% male participants, respectively. The FYP study did not delineate between male and female
participants. Most of the trials had fewer than 100 participants and a short duration of follow up,
warranting larger studies including a larger proportion of women to validate initial findings.
Availability and feasibility of administration are also potential limitations of integrative
medicine approaches. For example, of the approaches mentioned, dynorphin would be a more
burdensome treatment option for patients because of the need for IV administration. The overall
safety, efficacy, and availability of integrative medicines cannot be guaranteed given potential
variances in the authenticity and purity of products resulting from a lack of governmental
regulation and pharmacopeial standards.
Preliminary literature searches identified a large body of evidence for the use of
acupuncture to relieve opioid withdrawal symptoms. Because of the widespread availability of
studies, systematic reviews, and meta-analyses involving acupuncture as well as the complexity
of technique, those studies were excluded. Although this study aimed to evaluate lesser-known
integrative medicine approaches, the elimination of analysis of acupuncture as an integrative
medicine approach may be considered a limitation to this review. Additionally, despite the
popularity of ibogaine and kratom, we did not identify studies with either natural product that
met our inclusion criteria.

Despite the limitations, integrative medicine may have the potential for alleviating opioid
withdrawal symptoms. In general, outcome measures improved over time but were confounded
by the natural course of opioid withdrawal resolution, specific characteristics of drug
dependency, and individual determination in recovery. The results of this systematic review
support the need for further research on integrative medicine for symptoms of opioid withdrawal.
1.4 Conclusions:
Limited data demonstrates that integrative medicine has potential benefits in lessening
opioid withdrawal symptoms without increasing the risk of adverse effects. Additional trials with
larger patient populations are necessary to provide stronger evidence to support the use of
integrative medicine approaches for OWS. Trials which focus on the feasibility of integrative
medicine as monotherapy for outpatient treatment may be of particular value. Further research is
necessary to adequately determine reliable approaches for opioid withdrawal symptoms.
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